Pharmacyclics, J&J drug shown to improve leukemia survival

May 31, 2014 11:41 AM

21 0

CHICAGO (Reuters) - A new drug for the most common form of leukemia in adults improves survival for patients whose disease has worsened despite standard treatment, according to late-stage study findings released on Saturday.

Ibrutinib, sold by Pharmacyclics Inc and Johnson & Johnson under the brand name Imbruvica, was approved by U.S. regulators for treatment of chronic lymphocytic leukemia in February.

Read more

To category page